Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11066364 | 0.82 | MMP1 (0.37) | MMP1MMP9MMP12CES2CES1 | |
| SCHEMBL6937163 | 0.79 | MMP1 (0.33) | MMP1MMP9MMP12CES2CES1 | |
| SCHEMBL10992653 | 0.78 | MMP1 (0.39) | MMP1MMP9MMP12CES2CES1 | |
| SCHEMBL6935699 | 0.78 | CA12 (0.37) | MMP1MMP9MMP12CES2CES1 | |
| Water SCHEMBL19138791 | 0.77 | MMP1 (0.38) | MMP1MMP9MMP12CES2CES1 | |
| Guanidine SCHEMBL28785879 | 0.75 | MMP1 (0.34) | MMP1MMP9MMP12CES2CES1 | |
| Water SCHEMBL19138790 | 0.74 | MMP1 (0.36) | MMP1MMP9MMP12CES2CES1 | |
| Water SCHEMBL19138830 | 0.74 | MMP1 (0.33) | MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL19138860 | 0.74 | MMP1 (0.33) | MMP1MMP9MMP12ALDH1A1 | |
| SCHEMBL6940864 | 0.70 | POLB (0.45) | ALDH1A1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | NEUROBO PHARMACEUTICALS INC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3653598-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Gemphire Therapeutics Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | NEUROBO PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10544100-B2 | Autophagy inhibitors | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-01-28 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | GEMPHIRE THERAPEUTICS INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2003103575-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003103599-A2 | CASPASE-1 INHIBITORS AND METHODS FOR THEIR USE | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003097053-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059258-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544100-B2 | Autophagy inhibitors | BECN1, ATG7, SQSTM1 | MMP1 4599/4885MMP9 4060/4885MMP12 3652/4885 |
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MMP1 987/4885MMP9 2380/4885MMP12 2444/4885 |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MMP1 2656/4885MMP9 681/4885MMP12 1056/4885 |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | ELOVL3, DGKI, ELOVL5 | MMP1 4616/4885MMP9 4649/4885MMP12 4631/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | MMP1 2705/4885MMP9 1664/4885MMP12 1939/4885 |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | DGKI, DGKA, SQLE | MMP1 4228/4885MMP9 4382/4885MMP12 4516/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MMP1 2656/4885MMP9 681/4885MMP12 1056/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MMP1 2656/4885MMP9 681/4885MMP12 1056/4885 |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | MMP1 4228/4885MMP9 4382/4885MMP12 4516/4885 |
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MMP1 987/4885MMP9 2380/4885MMP12 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.